Read the Article ›
REGENERON

LATEST NEWS:

Alnylam and Regeneron Announce a Broad Collaboration to Discover, Develop and Commercialize New RNAi Therapeutics for Ocular and Central Nervous System (CNS) Diseases.

Fast Company

We’re honored to be recognized as one of the World's 50 Most Innovative Companies!

No. 3 in Biotech & No. 32 overall

To those who say “impossible, impractical, unrealistic,” we say:

Challenge Accepted

We’re relentless in our pursuit of new treatments because patients shouldn't have to wait for hope.

Rose, living with acute
hepatic porphyria

We are developing a new class of innovative medicines called

RNAi Therapeutics

that we believe have the potential to transform the lives of people living with rare diseases.

Dane, living with
hATTR amyloidosis

We are focused on diseases for which treatment options are limited or simply don't exist.

Our Robust Pipeline

includes investigational RNAi therapeutics for rare genetic, cardio-metabolic, hepatic infectious, and CNS and ocular diseases.

LATEST NEWS:

Alnylam and Regeneron Announce a Broad Collaboration to Discover, Develop and Commercialize New RNAi Therapeutics for Ocular and Central Nervous System (CNS) Diseases.

 

LATEST NEWS:

Alnylam and Regeneron Announce a Broad Collaboration to Discover, Develop and Commercialize New RNAi Therapeutics for Ocular and Central Nervous System (CNS) Diseases.

 

We’re honored to be recognized as one of the World's 50 Most Innovative Companies!

No. 3 in Biotech & No. 32 overall

 

To those who say "impossible, impractical, unrealistic,"  we say:

CHALLENGE ACCEPTED

We're relentless in our pursuit of new treatments because patients shouldn't have to wait for hope.

Rose, living with acute hepatic porphyria

We are developing a new class of innovative medicines called

RNAi THERAPEUTICS

that we believe have the potential to transform the lives of people living with rare diseases.

Dane, living with hATTR amyloidosis

We are focused on diseases for which treatment options are limited or simply don't exist.

OUR ROBUST PIPELINE

includes investigational RNAi therapeutics for rare genetic, cardio-metabolic, hepatic infectious, and CNS and ocular diseases.

 

APPROVED FOR PATIENTS IN THE U.S.

LATEST NEWS

>1k
Employees
16
Countries
10
Programs Currently in Clinical Development
1
Approved Product*
>35
Clinical Studies to Date
>5yrs
Longest Duration of Exposure

Updated as of March 2019
* In the U.S. and European Union

 
 
 
 
>1k
 
 
Employees
 
 
 
 
16
 
 
Countries
 
 
 
 
10
 
 
Programs Currently in
Clinical Development
 
 
 
 
1
 
 
Approved Product*
 
 
 
 
>35
 
 
Clinical Studies
to Date
 
 
 
 
>5yrs
 
 
Longest Duration
of Exposure

Updated as of March 2019
* In the U.S. and European Union

OUR FOCUS ON PATIENTS

A Family Living with
 hATTR Amyloidosis

Candace: Living with
Porphyria

A Family Living with
Primary Hyperoxaluria Type 1 (PH1)

OUR

PIPELINE

Late Stage

Learn more about our investigational therapies in hereditary ATTR amyloidosis, hemophilia, acute hepatic porphyria, and primary hyperoxaluria type 1.

Early Stage

 

Learn more about our investigational therapies across multiple disease areas.

WORK WITH US

Join Us

We are looking for innovators to join our team—help us realize our commitment to developing a new class of medicines for patients with limited or inadequate options.

View Job Openings >

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site